Vincerx Pharma, Inc. (NASDAQ:VINC) Short Interest Up 36.2% in June

Vincerx Pharma, Inc. (NASDAQ:VINC) was the recipient of a large growth in short interest during the month of June. As of June 30th, there was short interest totalling 590,000 shares, a growth of 36.2% from the June 15th total of 433,200 shares. Based on an average daily volume of 684,400 shares, the short-interest ratio is presently 0.9 days.

Analyst Ratings Changes

Separately, Cantor Fitzgerald restated an “overweight” rating on shares of Vincerx Pharma in a research report on Tuesday, April 9th.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Vincerx Pharma stock. Vanguard Group Inc. grew its stake in shares of Vincerx Pharma, Inc. (NASDAQ:VINC) by 29.9% in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 666,995 shares of the company’s stock after buying an additional 153,575 shares during the period. Vanguard Group Inc. owned 3.12% of Vincerx Pharma worth $3,375,000 as of its most recent SEC filing. Institutional investors and hedge funds own 44.02% of the company’s stock.

Vincerx Pharma Price Performance

Shares of Vincerx Pharma stock opened at $0.69 on Monday. Vincerx Pharma has a 1 year low of $0.57 and a 1 year high of $9.37. The company has a market capitalization of $20.56 million, a P/E ratio of -0.39 and a beta of 1.47. The business has a 50 day moving average price of $0.70 and a 200 day moving average price of $2.06.

Vincerx Pharma (NASDAQ:VINC) last issued its quarterly earnings results on Tuesday, May 14th. The company reported ($0.34) earnings per share for the quarter, missing the consensus estimate of ($0.26) by ($0.08). As a group, research analysts expect that Vincerx Pharma will post -0.62 EPS for the current fiscal year.

Vincerx Pharma Company Profile

Vincerx Pharma, Inc, a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. It is developing enitociclib, a cyclin-dependent kinase-9 inhibitor that is in Phase 1 clinical trials for treating patients with hematologic malignancies; and VIP236, a small molecule drug conjugate that is in Phase 1 clinical trials to treat solid tumors.